Meeting
2017 ASCO Annual Meeting
Safety and tolerability of the dual PI3K/mTOR inhibitor LY3023414 in combination with fulvestrant in treatment refractory advanced breast cancer patients.
Authors
Anna M. Varghese
Memorial Sloan Kettering Cancer Center, New York, NY
Anna M. Varghese , Kathleen N. Moore , Erika Paige Hamilton , David Michael Hyman , Komal L. Jhaveri , Xuejing Aimee Wang , Sophie Callies , Aaron Alan Fink , Volker Wacheck , Johanna C. Bendell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT01655225
Citation
J Clin Oncol 35, 2017 (suppl; abstr 1064)
DOI
10.1200/JCO.2017.35.15_suppl.1064
Abstract #
1064
Poster Bd #
56
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer.
First Author: Kathleen N. Moore
Poster
2024 ASCO Annual Meeting
First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer.
First Author: Cristina Saura
Poster
2023 ASCO Annual Meeting
A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor–positive (ER+)/HER2-negative (HER2-) breast cancer.
First Author: Virginia F. Borges
Poster
2016 ASCO Annual Meeting
Phase I study of the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin, and dacomitinib.
First Author: Zev A. Wainberg